Archive | October, 2013

Risk Rising in Mid and Small Cap Biopharmaceutical Stocks Update 2p EDT

Profit Taking Continues With Speculative Biotech Stocks Many of you who trade biopharmaceutical stocks know that $1B  may be considered a small cap stock. As we mentioned in yesterday’s post there is weakness in many high flying biotech stocks compared to the larger caps. Today the weakness is more pronounced in many “smaller” cap stocks: […]

Continue Reading 0

Biotechnology Bull Market Gets Second Wind To All Time Highs: ALR, GILD, ILMN,

Dow, S&P and Biotech Sector Hit All Time Highs NASDAQ Still 1000+Pts Under 2000 High Levels After a 10% sell-off in early October many large cap biopharmaceutical and diagnostic stocks are at new highs with the major indices at or near their October highs. The bellwether ETF IBB ($211.30) is flat after the index was […]

Continue Reading 0

Rayno Life Science Update #2: ALKS, ALXN, IMGN Up on Q3 Reports

Biopharmaceutical stocks were somewhat mixed today yet we have some nice moves in our portfolio: Alexion (ALXN $125.26) up 7.34% on Q3 Results which showed a 36% increase in sales to $400M and Net Income (GAAP) of $93.8M up from $92.2M in the same quarter of 2012. The Company has $1.3B in cash. A growing pipeline […]

Continue Reading 0

Rayno Life Science Update: CPHD,CSII,ILMN are Big Movers

Biotech Stocks Have Recovered From Early October Lows We have been traveling for two weeks and have not posted new content nor made portfolio changes. Despite a significant correction in the biotech sector in early October when major ETFs (IBB)  and funds such as the Fidelity Select Biotech Fund (FBIOX) dipped 8-10% briefly from Oct.4-10, […]

Continue Reading 0

Travel Notice//Update 2 10/21

Expect to be back by 10/25 in the meantime see previous two posts. Biotech stocks remain choppy. Hold mode with 10% cash.   Big action has moved to Internets and new media. See Raynoreport.com for market updates. ________________………… Futures are up almost 1% as of 8:50a EDT 10/10/13 IBB should stabilize well above support of […]

Continue Reading 0

Valuation Models for Biopharmaceutical Stocks

Are Biotech Valuations in the “Bubblet” Phase? In September of 2013 we wrote about the valuations of biotechnology companies from an M&A perspective after the acquisition of Onyx Pharmaceuticals (ONXX) by Amgen at a price of $10.4B. We will attempt to develop a model going forward that provides valuation metrics for emerging biopharmaceutical companies that have promising pipelines and are ramping […]

Continue Reading 0

Risk is Rising-Caution in Biopharmaceutical Stocks

Our Indicators Flash a Caution Signal Today No Change in Portfolio Picks If you are not at 10% cash in your biotechnology portfolio it is time to take profits or hedge your portfolio. If your biotech stock did not hit a new high last week you may want to sell it. Risk is rising and […]

Continue Reading 0

Market Sell-Off Accelerating As Shut-Down Drags On Update 10/4 CLDX

Life Science Trading Update 10/4/13       NASDAQ up 0.88% at 3809 Is the market expecting Boehner to settle? Green screen today with most market leaders up  about 2%: AMGN, BIIB, PCYC, REGN, VPHM. ETFs up in the 1% range. DX and Tools Movers: GHDX, ILMN. Mid and small-cap biopharmaceuticals: very strong except notable weakness […]

Continue Reading 0

Rayno Biopharmaceuticals Portfolio YTD Performance and New Highs: PCYC,SGEN,REGN

Biotech Stocks Hit New Highs Unfazed By Shutdown Biopharmaceutical stocks continued their blazing Q3 run today buoyed by assumptions that demand for pharmaceuticals will increase with 55 million new potential patients from Obamacare and that healthcare stocks are less affected by a weaker economy or a dysfunctional government. Moreover momentum is driven by M&A talk, […]

Continue Reading 0